delcetravir
/ Esfam Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 12, 2022
A Dose Escalation Phase 1 Study Evaluating the Safety and Pharmacokinetics of an Inhaled COVID-19 Inhibitor Delcetravir in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=8 | Not yet recruiting | Sponsor: Esfam Biotech Pty Ltd
New P1 trial • Infectious Disease • Novel Coronavirus Disease
1 to 1
Of
1
Go to page
1